The CNE Health blog reports that Pfizer is to take UK’s National Institute for Clinical Excellence (NICE) to court because of its refusal to allow tax money to be spent on its new drug for Alzheimer’s disease. In a perfect system, NICE would not exist. But given our socialist healthcare system, I do not really like the idea of companies like Pfizer expecting that taxpayers must cough up the cash regardless of whether a treatment offers value for money. And to be fair, under a social insurance system or other private system, insurance companies would still make NICE-type decisions about whether something delivers value.
Meanwhile, Pfizer continues to lobby for taxpayers to pay more for pharmaceuticals by arguing for the end of the free trade in pharmaceuticals in Europe.